AI in Biopharma Innovation and Regulatory Challenges – with Nishtha Jain of Takeda Pharmaceuticals
As life sciences organizations race to adopt AI, the biopharmaceutical sector remains one of the most complex and high‑stakes environments for implementation. The median cost to develop a new drug is $708 million, according to the RAND corporation, rising to an average of $1.3 billion when accounting for failures and capital costs. According to the…